LONG MINI-FUTURE - GENMAB | Market Closed - Boerse Frankfurt Warrants 13:55:02 2024-06-25 EDT | ||
| 2.13 EUR | -2.29% |
|
| Current month | -49.41% | ||
| 1 month | -50.92% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 2.13 | -2.29% |
| 24-06-24 | 2.18 | -3.96% |
| 24-06-20 | 2.27 | +21.39% |
| 24-06-19 | 1.87 | -13.02% |
| 24-06-18 | 2.15 | -6.52% |
Real-time Boerse Frankfurt Warrants
Last update June 25, 2024 at 01:55 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GENMAB A/S |
| Issuer | 
Vontobel
|
| WKN | VP2AVZ |
| ISIN | DE000VP2AVZ4 |
| Date issued | 2020-04-06 |
| Strike | 1,623 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.9 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 24.85 € |
|---|---|
| Lowest since issue | 1.25 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,799
DKK
Average target price
2,464
DKK
Spread / Average Target
+36.96%
- Stock Market
- Certificates
- Certificat
